RESUMO
Soy protein isolate (SPI) is known to reduce the risk of heart disease by lowering serum cholesterol and triacylglycerol (TG) levels. Soybean beta-conglycinin, which is a component of SPI, might be the active ingredient that prevents and/or ameliorates lifestyle-related diseases, such as hyperlipidemia and obesity. This study aimed to determine the efficacy of soybean beta-conglycinin for lowering the human serum TG level and visceral fat. Randomized double-blind placebo-controlled designs were used to test the effect of dietary beta-conglycinin, which was taken in the form of candy. [Test 1]In order to examine the serum TG level, 138 volunteers aged 26 to 69 years with TG concentrations above 1.69 mmol/L participated in the study. The subjects were divided at random into two different groups: the test group only consumed the experimental candy containing beta-conglycinin and the placebo group only consumed the placebo candy containing casein. The test period consisted of a 2-wk pre-evaluation phase to screen the participants, a 12-wk consumption period and a 4-wk post-evaluation phase. The serum TG concentrations were significantly reduced in the test group, compared with the placebo group, after consuming the experimental candy. [Test 2]In order to measure visceral fat by means of CT scanning, 102 volunteers aged 26 to 69 years with body mass indices (BMI) between 25 and 30 participated in the study. The subjects were divided at random into two different groups as for Test 1. The test period consisted of a 2-wk pre-evaluation phase to screen the participants, a 20-wk consumption period and a 4-wk post-evaluation phase. A significant reduction in visceral fat only occurred in the beta-conglycinin group. This study showed that beta-conglycinin is an effective food ingredient that will be of use to reduce high serum TG concentrations and to prevent obesity.
Assuntos
Fármacos Antiobesidade/farmacologia , Suplementos Nutricionais , Globulinas/farmacologia , Hipertrigliceridemia/tratamento farmacológico , Gordura Intra-Abdominal/efeitos dos fármacos , Proteínas de Soja/farmacologia , Triglicerídeos/sangue , Adulto , Idoso , Antígenos de Plantas , Apolipoproteínas/efeitos dos fármacos , Método Duplo-Cego , Feminino , Humanos , Metabolismo dos Lipídeos/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Proteínas de Armazenamento de Sementes , Triglicerídeos/metabolismoRESUMO
beta-Conglycinin decreased blood triacylglycerol (TAG) levels in male Wistar adult rats. Liver mitochondrial carnitine palmitoyltransferase activity in the beta-conglycinin-fed group significantly increased as against the casein-fed group. Hepatic fatty acid synthase activity in the beta-conglycinin group significantly decreased as against that of the casein-fed group. Fecal fatty acid excretion in the beta-conglycinin group was significantly higher than in the casein group.
Assuntos
Globulinas/farmacologia , Metabolismo dos Lipídeos , Fígado/efeitos dos fármacos , Fígado/enzimologia , Proteínas de Soja/farmacologia , Animais , Antígenos de Plantas , Carnitina O-Palmitoiltransferase/análise , Ácido Graxo Sintases/análise , Ácidos Graxos/análise , Fezes/química , Masculino , Ratos , Ratos Wistar , Proteínas de Armazenamento de Sementes , Triglicerídeos/sangueRESUMO
Human recombinant ER-60 was confirmed to have transglutaminase activity by a microtiter plate assay. Transglutaminase activity of ER-60 did not require calcium and was inhibited by cystamine, a substrate analogue. In addition, the transglutaminase activity of ER-60 was not inhibited by SH-blocking reagents. These results suggest that the properties of the transglutaminase activity of ER-60 are different from those in the cases of known mammalian transglutaminases of which the active site includes a cysteine residue.